IP Library › Granted Patent US 11,980,630
Granted Patent B2
US 11,980,630 · App. 17/569,804 · Granted May 14, 2024

Flex-nucleoside analogues, novel therapeutics against filoviruses and flaviviruses

Inventor: Katherine L. Radtke (Baltimore, MD)
Assignee: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
A61K31/683A61K31/506A61K31/675A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,980,630
App. No.
17/569,804
Granted
May 14, 2024
Kind
B2
Abstract

The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses.

Claims (5)

1. A fleximer nucleoside analogue selected from the group consisting of:

and a pharmaceutically acceptable salt, isomer, hydrate, prodrug or solvate thereof.

2. The fleximer nucleoside analogue according to claim 1 , having antiviral activity that inhibits or reduces the effects of a filovirus, flavivirus or coronavirus in a subject.

3. The fleximer nucleoside analogue according to claim 1 , in a composition further comprising a pharmaceutically acceptable carrier.

4. The fleximer nucleoside analogue according to claim 1 , in a composition further comprising an additional antiviral agent.

Continuity (3)
Division 16629057
Provisional Application 62539034 · Jul 31, 2017
Related Publication 20220133756A1 · May 5, 2022